No profile data available.
GT Biopharma, Inc. (GTBP) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in San Francisco, United States, with about 1 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$34.45 million. Its market capitalization was $12.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.
GT Biopharma reported $0 in revenue for fiscal year 2025.
$12.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Vyome Holdings, Inc. (HIND), Aida Pharmaceuticals, Inc. (AIDA), Fluent Corp. (CNTMF), Aspire Biopharma Holdings, Inc. (ASBP).